Infertility
Conditions
Keywords
Ovarian stimulation, LH inhibition
Brief summary
Currently, controlled ovarian stimulation (COS) in oocyte donors is performed by daily injections of gonadotropins( recombinant FSH) plus a GnRH Antagonist usually form 5th-6th stimulation day until ovulation induction with a bolus of another injection of a gonadotropin-releasing hormone (GnRH) Agonist. Injections of the GnRH Antagonist avoid untimely luteinizing hormone (LH) surge and spontaneous ovulation prior to follicular aspiration. There is a preparation of long-acting recombinant follicle stimulating hormone (rFSH= (corifollitropin alfa (FSH-CTP), Elonva®, MSD), that allows that a single subcutaneous injection substitutes the first 7 days of daily gonadotropin injections. On the other hand, a contraceptive oral progesterone only( Desogestrel, DSG) is available for contraception, avoiding the LH surge. It has been described the usefulness of orally administered medroxyprogesterone acetate, 10 mg to inhibit the endogenous LH surge in IVF patients during COS. In donors, by administering a single injection of FSH-CTP and oral desogestrel since the first menstruation day, the total number of injections administered is reduced and less discomfort is experienced without adverse impact on ovarian response. No description of the hormonal and ovarian response under this protocol has been published
Detailed description
* oral desogestrel since the first menstruation day, * a single injection of FSH-CTP on the 7th menstrual cycle day * routine monitoring of ovarian response with transvaginal ultrasound every second day until pre-ovulatory bolus of GnRH * Hormones measured on day of 7th menstrual cycle day , day of pre-ovulatory bolus of GnRH and the day after the bolus ( estradiol, FSH, Progesterone, LH) * Quality of Life questionnaire the day after the bolus
Interventions
DRUGFSH-CTP + DESOGESTREL
Hormones measured on day of 7th menstrual cycle day , day of pre-ovulatory bolus of GnRH and the day after the bolus ( estradiol, FSH, Progesterone, LH) \- Quality of Life questionnaire the day after the bolus
Sponsors
Fundación Dexeus Salud de la Mujer
Fundacion Dexeus
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 35 Years
Healthy volunteers
Yes
Inclusion criteria
* Population: donors (18-35 ) from candidates of Donor program * Fulfilling inclusión medical and legal criteria (RD -Ley de transposición de la normativa europea a la legislación española 9/2014) * Who had had undergone previously convencional COS (controlled ovarian stimulation) with FSH-CTP and daily antagonist injections * Given signed consent form.
Exclusion criteria
* Previous low response to COS * Previous ovarian hyperstimulation syndrome. * Ovarian cysts.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Total dose of gonadotrophins | At the end of the stimulation treatment period (5 or 7 days after begining of treatment) | Total Consume of gonadotrophins |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of mature oocytes | Day of oocyte recovery | — |
| Plasma LH | Day of GnrH bolus | Level of LH in plasma (mIU/ml) |
Countries
Spain
Outcome results
None listed